Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06507891
Status:
TERMINATED
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
A Clinical Study to Evaluate the Tolerance Pharmacokinetics and Efficacy of TQ-A3334 Tablets
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase Ib Open-label Dose Escalation and Expansion Study to Evaluate the Tolerance Pharmacokinetics and Effectiveness of TQ-A3334 Tablets in Patients With Advanced Non-small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
After considering the companys project situation and strategic development direction it has been decided to terminate this project The experiment will be terminated for non safety reasons
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to evaluate the tolerance dose-limiting toxicity DLT and maximum tolerated dose MTD of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules in patients with non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None